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COMPARISON OF RISK OF MALIGNANCY INDEX WITH 
HISTOPATHOLOGICAL EXAMINATION IN 
OVARIAN TUMORS 
INTRODUCTION : 
Ovarian cancer, the most lethal of all gynaecological malignancy 
represents a significant public health problem to a woman worldwide. It 
is often asymptomatic at an earlier stage, many of them present in an 
advanced stage for which the five year survival rate remains low(1).The 
most important prognostic factor is the quality of primary cytoreductive 
surgery, and it depends on skills and experience of gynecologic 
oncologist. It is important to discriminate between benign and malignant 
tumor for selective referral of patients.(2) 
 
The current challenges associated with ovarian tumor results from 
a lack of effective screening strategies, difficulty in detecting the disease 
at an earlier stage and the disappointing impact of treatment regimens.  
 
In Various studies it has been shown that the diagnosis of ovarian 
tumor by investigations like Ultrasonagram, Doppler, MRI, CT has been 
proved to be uncertain despite the need for expertise and they are not cost 
effective. 
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The risk of malignancy index is a simple scoring system based on 
combination of various clinical features. It has been developed to 
improve diagnostic accuracy for ovarian malignancy. This helps in 
selective referral of relevant patients to specialized cancer centers.            
Jacob et al (3) in 1990, developed a scoring system, Risk of malignancy 
index based on the ultrasound score, menopausal status and CA 125 value 
which were obtained preoperatively. 
 
RMI at a cut off level of 200 was found to be very effective in 
discriminating between benign and malignant ovarian mass. Later, 
Tingulstad et al (4) 1996 developed RMI 2 and further it was modified by 
him as RMI 3(5) in 1999.  Yamamoto et al in 2009(6) developed a new 
RMI, RMI 4 where he included tumor size score. 
 
The purpose of this study was to evaluate the risk of malignancy   
index with USG score, CA-125 and menopausal status in differentiating   
benign and malignant ovarian masses. 
 
 
 
 
 
 
2 
 
GROSS ANATOMY : 
 
LOCATION : 
Ovaries are paired structures located within the lesser pelvis on 
each side of the uterus closer to the lateral pelvic wall in the ovarian fossa 
at the bifurcation of common iliac artery.(1) It is the only structure in the 
pelvic cavity which is extra peritoneal. 
 
BOUNDARIES : 
Anteriorly it is bounded by obliterated umbilical ligament, by 
ureter and internal iliac artery posteriorly, tubal extremity attached to 
fimbrial end of uterine tube, peritoneal suspensory ligament of ovary 
which contains ovarian vessels and nerves, uterine extremity (lower pole) 
which is narrower than the tubal extremity is attached to lateral angle of 
uterus by ovarian ligament, posteroinferior to the uterine tube 
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Each ovary is almond shape, about 3cm long, 1.5cm wide,1cm 
thick, with a volume  of 6 cm3. Before ovulation begins they are grayish 
pink with smooth exterior surface. After regular ovulation the surface 
become distorted by the scarring which follows the degeneration of 
successive corpus lutea. 
 
BLOOD SUPPLY : 
Blood supply to the ovary is through the ovarian artery both of 
which originate directly from the descending aorta. Both ovarian artery 
and vein enter and exit at the hilum of ovary through the suspensory 
ligament .The left ovarian vein empties into the left renal vein, and the 
right ovarian vein drains directly into the inferior vena cava.  Nerve 
supply is through the ovarian, hypogastric and aortic plexus, which runs 
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with the vasculature through the suspensory ligament of the ovary, 
entering the ovary at the hilum. Lymphatic drainage of the ovary is 
mainly is to the lateral aortic nodes; However, the iliac nodes are also 
involved. 
 
EMBRYOLOGY: 
On the medial side of the mesonephros Coelomic epithelium 
thickened to form a genital ridge. From this germinal epithelium sex 
cords of cells proliferate and grow into underlying mesoderm. From the 
yolk sac primordial germ cells migrate to the region of developing ovary 
and gives rise to oocytes. Each primordial germ cells are surrounded by 
small masses of cells which are formed by breakdown of sex cords to 
form primordial follicle. 
 
Ovaries are first found in lumbar region from where it descend 
down to pelvis. A gubernaculum extends from ovary to labia majora . 
Part of gubernaculum between ovary and uterus to form ligament of 
ovary, part of it between uterus and labia majora to form round ligament 
of ovary.   
 
 
 
 
5 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
7th week 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
20-24WK 
 
6 
 
 
 
 
 
 
 
 
 
 
 
 
7 
 
HISTOLOGY: 
Ovary has cortex and medulla. Cortex contains follicles in various 
stages of development. Medulla is made of dense connective tissue which 
contains vessels, nerves and lymphatics. 
         
STAGES OF FOLLICULAR MATURATION 
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Primordial follicle is an oocyte surrounded by single layer of 
follicular cells, the squamous epithelium, resting in prophase stage. 
 
In primary follicle squamous cells enlarge and become cuboidal to 
form granulosa cells which later on give rise to corona radiata. 
Proteoglycan rich zona pellucida is secreted by oocyte between its surface 
and surrounding granulosa cells. Primary follicle contains theca externa, 
theca interna, zona pellucida with gap junctions. Mass of follicular cells 
increase in size to form secondary follicle. Fluid filled cavities begin to 
form between them containing clear fluid. These cavities fuse to form one 
large fluid filled space surrounded by thin granulosa cells, thickened at 
one pole to form cumulus oophoricus.  
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HISTOLOGICAL PICTURE OF FOLLICLES 
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AIM OF THE STUDY 
 
To evaluate the risk of malignancy index based on CA125, 
menopausal status and ultrasound score in women with ovarian mass, to 
arrive at an optimal cut off point of RMI score. 
 
To evaluate the performance of individual parameters and RMI in 
differentiating benign and malignant ovarian tumors. 
 
To validate the efficiency of risk of malignancy index in 
discriminating benign and malignant ovarian tumors. 
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REVIEW OF LITERATURE 
 
Ovary being a complex organ involved by variety of neoplasms 
accounts for 10-15% of all gynaecological cancer in developing 
countries(4). Of female genital tract malignancy, ovary is the third most 
common site in Indian women and they account for 6% of all cancer in 
female. Tumors primarily from the ovary constitute 80% while 20% of 
the tumors are from colon, breast, stomach and uterus. The incidence as 
well as the survival has been increased for the past 2 decades.  
 
Incidence of ovarian tumor increases with age, peak at about 60yrs 
of age. Around 80% of the ovarian cancer are epithelial adenocarcinoma 
of which two-third of them will be in advanced stage at the time of 
diagnosis(4).Only 3% of ovarian cancer are seen in women younger than 
35yrs and majority of them are germ cell tumors(3). In premenopausal 
women only about 7% of ovarian epithelial tumors are frankly malignant, 
whereas in postmenopausal women about 30% are malignant(5).A 
women’s risk at birth of having ovarian cancer in her life time is around 
1%-1.5% and that of dying from ovarian cancer is almost 0.5%. 
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RISK FACTORS: 
Main risk factors for epithelial ovarian cancer are  
- Reproductive history 
- Genetic susceptibility 
 
‘’NUMBER OF OVULATORY CYCLES IN A LIFE TIME 
BEING THE   MAJOR RISK FACTOR’’ 
 
Nulliparous women were at 1.5 times the risk of parous women 
(Donn & Cuttler 1955).Risk decreases with increase in number of full 
term pregnancies. In a recent US case control study 563 cases, and 523 
controls  it was found that there as a reduction in risk of 40% with one 
child,60% with 2 children,80% with five or more children (TITUS; 
ERNSTOFF ET AL2001). Cohort study conducted in Norway yielding 
445 cases found 0.9RR for parity 1, 0.6 RR for parity 2, 0.5 RR for parity 
3 or 4 in comparison to nulliparous women 10. (Kvace et al 1988).  
 
Menstrual factors are less important than parity in an ovarian cancer 
risk. Menarche at an earlier age (<12) are at about 25% greater risk than 
those with late menarche (>15yr)(11) RISCH 1998. Women with irregular 
cycle length, early menopause are protective. 
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EXOGENOUS HORMONES : 
Combined oral contraceptive pills has a protective effect for 
ovarian cancer which has been proved beyond doubt (IARC 1999)12. Risk 
of ovarian cancer reduced by about 50% with 5 year use and protection 
increases with duration of use. (HANKINSON ET AL 1992)13 
(WHITEMORE ET AL). After cessation of use the effect last for around 
15 years (BERAL ET AL 1999)14. Hormone replacement therapy has 
minimal effect on ovarian cancer (WHITEMORE ET AL 1992)15 while in 
some have reported a moderate increase in risk (IARC1999). 
 
GENETIC SUSCEPTIBILITY: 
Ovarian cancer tends to aggravate in families and such cancers 
tend to occur in younger age. Inheritance has a significant role in about 
5% epithelial ovarian cancer, and they are usually serous 
adenocarcinoma. BRCA1, BRCA2 Mutations are implicated in 5-10% of 
malignant ovarian tumours., They also have an increased risk for lynch 
syndrome (colon, endometrium, ovarian cancer)16. Women with an 
inherited BRCA1 gene has 66% risk of breast cancer and 40-50% risk of 
ovarian cancer .With BRCA2 penetrance of breast cancer is 80% but for 
ovarian cancer penetrance is only 25% .With one affected family 
member, relative risk of ovarian cancer was found to be 3,and with 2 
relative risk was found to be 7. Prophylactic Oopherectomy considered in 
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BRCA1 Mutation carrier  as they have a lifetime risk of around 36% 
(Risch et al 2001) of developing ovarian cancer. 
 
OTHER FACTORS: 
DIETARY FACTORS: 
Case control studies in both China(20) & Italy(21) found that high 
intake of fat and meat are associated with ovarian cancer. In Italian study, 
it was found that red meat increase the risk by 50% while vegetables 
decreases it by 50%.  
 
Use of talc powder in genital hygeine associated with 1.5 relative 
risk of ovarian Cancer. 
 
CLINICAL FEATURES: 
Majority of women with ovarian mass are asymptomatic in an 
earlier stage, they often present with vague and nonspecific symptoms.  
In pre and postmenopausal women, the presence of vague symptoms like 
dyspepsia, early satiety, loss of appetite, urinary frequency and / or 
urgency, altered bowel habits for more than 12 days per month should 
alert the treating physician. In the reproductive age group ovarian masses 
are mostly functional and can be managed conservatively or with minimal 
invasive procedures. The Probability of malignancy is high in pre and 
postmenopausal women and they should be properly investigated and 
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evaluated. Careful physical examination, imaging techniques will be 
helpful in arriving at a diagnosis. The Ultrasonogram is the preliminary 
imaging technique in patients with pelvic adnexal masses. Used in 
screening (endometrium, ovary), diagnosis (evaluation of the adnexal 
mass) and follow-up of therapy for detection of recurrences. Ovarian 
cancers are detected in late stages due to lack of symptoms so the 5-year 
survival rate of women with epithelial ovarian cancers has not changed 
much over the years despite the advances in surgery  and chemotherapy. 
Ultrasound is used as a screening tool for ovarian malignancy based on its 
ability to detect tumors which are asymptomatic and not clinically 
palpable. In the early days, ultrasound was used alone and was not 
considered as a useful tool for screening.  
 
The feature that are suggestive of malignancy in an ultrasonogram  are 
1. Bilateral lesion 
2. Multiloculated lesion 
3. Ovarian volume more than 10cm3 
4. Cyst wall thickness more than 3mm 
5. Septal thickness more than 2mm 
6. Solid component / complex mass (Solid & Cystic) 
7. Papillary excrescences 
8. Increase in vascularity 
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9. Doppler resistance index less than 0.40 (RI < 0.40) 
10. Presence of ascites 
11. Presence of intrabdominal metastasis 
 
The sensitivity of USG is high but the specificity is low for 
diagnosis of early ovarian malignancy. Granberg et al in 1993(24), reported 
that ultrasound reliably predicts ovarian cyst characteristics. The 
percentage of malignancy was 0.3% in unilocular cyst, 7% in unilocular 
cyst with solid component, 36% multilocular lesion and 39% in solid 
tumor.              
 
Sassone et al (25) in 1991 developed index based on 4 different 
ultrasonographic features like structure of internal wall, thickness of the 
wall, the presence of septations and echogenicity.   It has 100% sensitive 
and 83% specific in differentiating benign from malignant ovarian 
masses. 
 
In 1993 De Priest et al(26) reported a index system based on 3 
structural characteristics, combined tumor volume, wall structure and 
septal structure. This was tested on 213 ovarian masses, sensitivity and 
specificity was found to be 89% and 70% respectively. 
 
Botta and Zarcone in 1995 compared the diagnostic accuracy of the 
Sassone[25] and De priest[26] scoring systems. It was found that cut of 
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value of 5 in De priest scoring system and cut off value of 9 in Sassone[25] 
scoring system  has a large number of false positive results. There was 
considerable overlapping of scores between benign and malignant 
tumors. They concluded that the addition of ovarian volume as a criteria 
did not improve the accuracy of scoring system. In 1997, Ferrazzi et al [27] 
produced a morphological scoring system tested on 330 ovarian tumors, a 
new multicenter score demonstrated a statistically significant diagnostic 
accuracy. This was due to addition of two new criteria that allowed 
correction for typical dermoids and 10 endohaemorrhagic corporalutea. 
This index has a sensitivity of 87% and specificity of 67%. This study 
gave better result than other previous scoring system (Sassone et al 
1991[25], Granberg etal[24] 1993 etc) in predicting the malignancy. 
However, none of these scoring systems have very high accuracy. 
 
CA 125: 
CA 125 is the serum based tumor marker used in screening of 
ovarian tumor first described by Bast and collegues in 1983. .It is also 
known as tumor associated protein because elevated levels does not 
always indicate ovarian malignancy, that is its levels can be high even 
without malignancy or disease. 
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CA 125 TEST: 
CA 125- cancer Antigen 125 (tumor cell surface signal) was so 
named because it was the 125th antibody tested against ovarian cancer 
cell.CA 125, a level of 35U was found to be the cut off, as 99% of 
healthy women will have values less than 35, while women with ovarian 
cancer will have values in hundreds even in thousands. CA 125 is not 
specific for ovarian cancer especially in reproductive age, where the 
various benign conditions associated with elevated CA 125 levels are 
more common. Hence in post menopausal women the cut off value of CA 
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125 in predicting malignancy is 35U/ml whereas the cut off value upto 
200 U/ml is not very predictive in premenopausal women. 
 
Only 50-60% of women with early stage, and 80-90% of women. 
With advanced stage ovarian cancer will have elevated values. Due to its 
low sensitivity and specificity, CA 125 values are not useful in screening 
the general population. However high risk women should be subjected to 
CA-125 test. 
 
CA-125 & FALSE ELEVATION: 
Low levels of CA125 are persistently released by normal tissues 
including ovarian cells, pancreatic cells, breast cells, and tissue lining the 
abdomen and chest. Ovarian cancer not only increases the number of cells 
that secrete CA125 but also inflames the lining of abdomen which 
contains normal cells that release CA125.So not only the ovarian cancer 
but also some other cancer in the abdomen elevates CA125 levels. Non 
cancerous condition which elevates the levels are inflammatory condition 
of the abdomen, (Diverticulitis, Peritonitis, Inflammatory bowel disease, 
Pelvic inflammatory bowel disease, tuberculosis, pancreatitis).  
 
Liver diseases, recent surgery, benign gynaecological conditions 
such as fibroid, endometriosis, ectopic pregnancy and ruptured cyst, 
pregnancy, lung and colon cancer. 
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FOUR MAJOR ROLE OF CA 125 : 
1. Predicts treatment outcome in women with ovarian cancer, 
fallopian tube cancer and   primary peritoneal cancer. 
 
2. Helps in detection of recurrent ovarian cancer.  
 
3. To monitor and asses the treatment effectiveness throughout the 
course of Chemotherapy. 
 
4. Used in screening of ovarian cancer, fallopian tube cancer, and 
primary peritoneal cancer in high risk cases .CA 125 test can be 
helpful but it is hard to interpret so serial measurement over a 
course of time may be helpful rather than a single value. 
 
Various other tumor markers used for screening ovarian cancer are 
HE4, CA 19-9, CA 15-3, lipid associated sialic acid, osteopontin etc. 
Proteomic analysis in serum of women with elevated CA125 which 
detects the proteins & protein fragments in the circulating   blood helps in 
differentiation of benign and malignant ovarian tumors.  The sensitivity, 
specificity and the positive predictive value of proteomic pattern are 
100%, 95% & 94% respectively. But its efficacy is yet to be studied in 
large population. In women with family history of epithelial ovarian 
cancer genetic testing is advocated. 
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None of the investigational modalities are proved to be efficient in 
differentiating benign and malignant ovarian tumors. To improve the 
sensitivity and specificity of the test in predicting the presence of 
malignancy a multimodal screening modalities was introduced, which 
combines various parameters Jacob et al(3) in 1990 introduced a new 
scoring system called Risk of Malignancy index (RMI). 
 
 RMI is based on the following 3parameters. 
1. Serum CA 125 level (U/ml). 
2. Ultrasound score.  
3. Menopausal status. 
 
Ultrasound findings such as bilateral lesions, multilocular cyst, 
presence of solid lesion, presence of metastasis, ascites. Each scored one 
point. If none of them are present ultrasound score is O,if  1 of the finding 
is present  then the score is 1 and  if 2 or more finding are seen then the  
score will be 3. 
 
1) The menopausal status (M),In  premenopausal M=1 and In 
Postmenopausal M=3 RMI is the multipled facor of  CA 125, 
Ultrasound score, and Menopausal status. It is expressed as, 
 
RMI = U x M x CA 125 
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            The sensitivity and specificity Of RMI with Cut off level of 200 
was found to be 71% and 96% respectively, positive predictive value of 
89% for diagnosing ovarian cancer. 
 
Davis et al in 1993 (28) conducted a study involving 124 patients to 
validate the Risk of malignancy index. This study confirmed that in 
differentiating benign and malignant  Risk of malignancy index  is more 
efficient than the individual criteria and the results were compared with 
the other scoring systems. In this study, the sensitivity and specificity of 
RMI was found to be 87% and 89% respectively. Hence concluded that 
RMI is a simple scoring system that will be helpful in differentiating 
benign from malignant ovarian lesion and provides an opportunity to 
refer appropriate cases to tertiary care centre, where surgery can be done 
by gynaec oncologist. 
 
In 1996 Tingulstad et al modified the risk of malignancy Index 
RMI1proposed by Jacob and named as RMI 2. The same parameters are 
used as in RMI 2 but the scoring system was altered.  
 
1. CA 125 level (value in U/ml) 
2. Menopausal score M ( Premenopausal  M=1,Postmenopausal =4) 
3. Ultrasound score U (based on USG features like bilateral lesion, 
multiloculation, solid lesion, ascites and metastasis. 
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Each parameters were given 1 point. If the points were 0 or 1 U=1, 
and if two or more parameters were present U=4. The sensitivity and 
specificity of RMI 2 was found to be 80% and 92% respectively and the 
positive predictive value of 83%.Comparison of RMI2 with RMI 1 
revealed that RMI 2 was efficient in predicting malignancy. 
 
Leelahakorn et al in 2005(29) studied the role of CA125, 
Menopausal status, and ultrasonographic score in discriminating benign 
and malignant ovarian tumors. In this study he had a sensitivity of 88.6%, 
specificity of 90.7%, positive predictive value of 70.5%, and negative 
predictive value 97% respectively.  
 
Tingulstad et al (5) in 1999 further modified RMI 2 which was 
previously modified from RMI 1 by altering the scoring values and it is 
now termed as RMI 3.  
 
The scoring of RMI 3 is different from RMI 1 and RMI 2. 
1. CA 125 value is the absolute value.  
2. Menopausal score in premenopausal M=1 and in Postmenopausal 
M=3(similar to RMI1). 
3. The ultrasound score U is based on presence of  like bilateral 
lesion, multiloculations, presence of solid areas, ascites and 
metastasis. 
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  Ultrasound  Score 0 or 1 made   U=1 
Score 2 or more made  U=3 
 
The study involving 365 patients with a cut off value of200, the 
sensitivity, specificity, positive predictive value and negative predictive 
value of RMI 3 was found to be 71.1%, 92%, 69% and 92% respectively.           
In Conclusion, it was found that RMI 3 has high sensitivity and 
specificity in diagnosing ovarian cancer. RMI scoring system is more 
efficient than individual parameter in discriminating ovarian tumor as 
benign or malignant.  
 
Morgante et al 1999(30), Leelahakorn et al 2005(29), in a study 
reported that with an ultrasonographic techniques alone sensitivity and 
specificity in diagnosing malignant ovarian cancer are 62% and 73% 
respectively. Benjapibal et al 2007(1), elevation of CA 125 is noted in 
85% of surface epithelial ovarian tumors. With a cut off of 35U/ml the 
sensitivity and specificity was 83% and 39.3% respectively. Yamamoto et 
al in 2009, further modified the risk of malignancy index by introducing 
tumor size score.                 
 
RMI 4 is the multiplied factor of CA 125 level, ultrasound score, 
and menopausal status and tumor size score. 
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RMI 4 = CA 125 x U x M x S.( CUT OFF VALUE 450 ) 
 
• CA 125 level – the absolute value in U/ml 
• Menopausal score In  Premenopausal  M=1 and in 
                                              Postmenopausal   M=4 
• U ,ultrasound score based on 
∗ Bilateral lesion 
∗ Multilocularity 
∗ Solid areas,  
∗ Ascites and  
∗ Metastasis 
 
U= 0 0r 1 made U=1 
U=2 or more made U=4 
 
• S tumor size score.  
S =1, if tumor size is < 7 cm in a single largest diameter and 
S =2 if tumor size is 7cm or more.  
 
The study showed that Inclusion of tumor size score in RMI 4 
improved the efficiency to diagnose malignancy. Comparing with other 
three indices RMI 4 has better sensitivity and specificity in differentiating 
malignant and benign ovarian tumors. This study has a sensitivity of 
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86.8%, specificity of 91%, positive predictive value of 97.5% and 
negative predictive value of 90%. It was concluded that RMI 4 was better 
than RMI 1, 2 & 3. 
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RISK OF MALIGNANCY INDEX 
 
 
S.NO PARAMETERS RMI 1 RMI 2 RMI3 RMI 4 
1 CA 125  U/ml U/ml U/ml U/ml 
2 Ultrasonogram score 
If U=0  
If U=1 
If U=2 or more 
 
U = 0 
U = 1 
U = 3 
 
U=1 
U=1 
U=4 
 
U = 1 
U = 1 
U = 3 
 
U = 1 
U = 1 
U = 4 
3 Menopausal Status 
  -Premenopausal  
 - Postmenopausal 
  
    1 
    3 
   
    1 
    4 
   
    1 
    3 
   
     1 
     4 
4 Tumor size score 
size <7cm 
size >7cm 
    
S = 1 
S = 2 
 
Manjunath et al in(31) 2001 reported a study , comparing the Risk of 
Malignancy indices RMI 1, 2 and RMI 3 in discriminating benign and 
malignant ovarian tumor. It was found there was no statistical difference 
in all three RMI indices in differentiating benign and malignant ovarian 
tumors.  
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In 1999 Twickler et al(32) devised “The Ovarian Tumor index’ to 
predict the risk for malignancy. The study involved 244 women, of which 
214 had benign lesions and 30 had malignant lesions. The ovarian tumor 
index is found to be accurate in predicting the ovarian malignancy by 
combining various parameters like age in years, ovarian volume, 
Sassone`s[7] morphology score, PI, central or septal location,peripheral 
location and echogenicity. 
 
In 2002 Torres et al(33) devised a study on 158 patients with ovarian 
mass and the study showed that the sensitivity and specificity of RMI to 
be 73% and 86% respectively. 
 
In 2003, Anderson et al (34) conducted a study involving 180 
patients to demonstrate the ability of RMI indiscriminating benign and 
malignant ovarian tumor. The sensitivity of RMI With cut off value of 
200 sensitivity, specificity, positive predictive value, and negative 
predictive value was found to be 70.6%, 87.7%, 66.1% and 89.8% 
respectively. 
 
Ma et al in 2003 devised a study on 140 patients and evaluated the 
Risk of Malignancy index in a woman with pelvic mass preoperatively. 
The sensitivity, specificity, positive predictive value and negative 
predictive value was found to be 87.3%, 84.4%, 82.17% and  89% 
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respectively. In conclusion, there was no statistically significant 
difference between RMI 1, RMI2, and RMI3 in differentiating benign and 
malignant ovarian tumor and also demonstrated that RMI to be valuable 
and in predicting ovarian tumor preoperatively.  
 
In 2004 Obeidat et al(35) conducted a  study  in 100 women with 
ovarian mass to validate the risk of malignancy index. The sensitivity, 
specificity, positive predictive value, negative predictive value was found 
to be 90%, 89%, 96% and 78% respectively  with cut off value of RMI 
200. They showed that RMI is a suitable scoring index. 
 
Van den Akker et al(36) in 2010 reported a study involving 548 
patients to evaluate the Risk of malignancy index  in daily basis.  With a 
cut off value of RMI 200, sensitivity, specificity, positive predictive value  
and negative predictive value  was found to be 81%,85%,48% and 96% 
respectively. RMI is a simple scoring system that helps in diagnosis 
ovarian cancer during the preoperative period. 
 
Leelahakorn et al (37) in 2005 conducted a study in 175 women with 
pelvic adnexal masses. With a cut off value of RMI 200, the sensitivity 
was 88.6%, specificity was 90.7%, positive predictive value was 70.5% 
and negative predictive value was 97%. The RMI which was calculated in 
the pre operative period was compared with histopathology report in the 
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post operative period. They concluded that RMI is a reliable scoring 
method in detection of ovarian malignancy. In this study, the Ultrasound 
scoring system of Ferrazzi et al 1997 (40) was used in the calculation of 
RMI. 
 
In 2007 Ulusoy et al(38) evaluated 296 patients with  adnexal 
masses with RMI. With the cutoff of 200 the sensitivity, specificity was, 
the positive predictive value and negative predictive value was found to 
be 71.7%, 80.5%, 67.3%, 83.6% respectively.  
 
Milan Terzic et al in 2011 conducted a study involving 81 patients 
out of which 51 had benign tumors and 30 had malignant ovarian 
tumors.With a cutoff value of RMI 200, the sensitivity, specificity, 
positive predictive value and negative predictive value was found to be 
83.33%,94.12%, 89.29%, 90.57% respectively.  
  
Rachmasari Putri et al in 2010 retrospectively analysed 90 patients 
and calculated the Risk of Malignancy index score. Out of 90 patients, 70 
Of them had malignancy and 20 of them had benign tumors. With the 
cutoff of RMI 200 the sensitivity, specificity, positive predictive value 
and negative predictive value was 70%, 75%, 90.74%, 41.67% 
respectively. They concluded that RMI is very reliable method in 
diagnosing malignancy. 
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Monirath Hav et al in 2011 conducted a study involving 151 
patients with adnexal masses. Out of them 132 patients are found to have 
benign mass, 19 were diagnosed to have malignant mass. The study 
showed that the performance of RMI was good with the cutoff value of 
RMI = 238. The sensitivity, specificity, the positive predictive value and 
negative predictive value was found to be 89.5%, 96.2%, 77.3%, 98.4% 
respectively. 
 
Erfan Akturk et al in 2012 devised a study that compares the four 
risk malignancy indices RMI 1, RMI 2, RMI 3 and RMI 4 involving 100 
patients with ovarian mass. The study concluded that there is no statistical 
difference between RMI 1, RMI 2 and RMI 3 at a cut off value of 200 
and RMI 4 at the cut off value of 500. The sensitivity, specificity, positive 
predictive value, negative predictive value of RMI1, RMI 2, RMI 3, RMI 
4 were obtained and there was no statistical difference between them  and 
their diagnostic performance were same. Thus RMI is a simple scoring 
system and any of them can be used even in unspecialised units and is 
highly useful in proper selection of patients who require referral to 
specialized centers. Risk of malignancy index further helps in 
differentiation of benign disease that needs conservative line of 
management or minimal invasive procedures, thus avoids unnecessary 
surgical exploration of patient with benign diseases. The study showed 
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the RMI should be the test of choice in discriminating benign and 
malignancy conditions in the preoperative evaluation of patients. 
 
Bouzari Z et al in 2012   reported a study in 182 patients presented 
with ovarian mass and evaluated the ability of RMI index in diagnosing 
malignant ovarian tumor. At a cut off value of 200, the sensitivity, 
specificity positive predictive value and negative predictive value of the 
RMI were 91.3%, 88%, 52% and 98.5% respectively. At a cutoff point of 
265 they concluded that the sensitivity, specificity, positive predictive 
value and negative predictive value were high in differentiating benign 
and malignant ovarian tumors. The sensitivity and specificity was 91.3% 
and 96.2% respectively at a cut-off point of 265 which was based on the 
receiver operating characteristic curve. 
 
Hakansson F et al in 2012 conducted a prospective study involving 
1159 patients with pelvic masses in tertiary oncology centre. The 
objective of the study was to assess the ability of RMI with cut off value 
of 200 for preoperative diagnosis of ovarian malignancy. The sensitivity, 
specificity, positive predictive value and negative predictive value were 
92%, 82%, 62%, 97% respectively. From the study, he concluded that 
Risk of malignancy index has high diagnostic performance in 
differentiating benign and malignant ovarian tumor which enables the 
patients to undergo further evaluation if needed. 
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In 2012 Wang et al (47) devised a study on 180 patients with ovarian 
tumor by applying an improved risk of malignancy index. The improved 
RMI is modified from Jacob et al by introducing colour doppler study and 
new tumor marker (Tumor specific growth factor).Improved RMI is 
redesigned by including ultrasound score, Tumor specific growth factor 
levels and colour doppler flow imaging result. Improved RMI has high 
sensitivity, specificity, positive predictive value and negative predictive 
value and therefore has a better performance in diagnosing malignant 
ovarian tumor than RMI. He showed that, in comparison of classic 
Jacob’s model the improved RMI was accurate in predicting germ cell 
tumor, granulosa cell tumor and ovarian malignancies in early stage when 
compared to Jacobs RMI. But this can be applicable only in tertiary 
centers where high level of expertise in ultrasonogram and sophisticated 
Doppler are available. 
 
Ovary being a complex organ said to be involved by wide variety 
of neoplasms. It is the only organ in the body which gives rise to galaxy 
of neoplasms. 
 
Ovarian tumors are classified into benign and malignant groups, 
and the third group intermediate between the two are called borderline 
ovarian tumor which was introduced by WHO and FIGO in 1971. 
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Borderline ovarian tumor, the tumor of low malignant potential 
shows higher proliferative activity when compared to benign neoplasms 
but does not show stromal invasion. They remain confined to the ovary 
for longer period, and are associated with a very good prognosis, occur 
predominantly in premenopausal women between the ages of 30 and 50 
years of age , while invasive carcinomas occur between the ages of 50 
and 70 years of age. 
 
The criteria for the diagnosis of borderline tumors are 
 Increased mitotic activity and nuclear atypia 
 No stromal invasion 
 Epithelial hyperplasia in the form of tufting, pseudostratification, 
cribriform and micropapillary structure 
 Detached cell clusters 
   
Most commonly ovarian tumor fall into   three major categories -
surface epithelial ovarian tumors, germ cell tumors and sex cord stromal 
tumor. They are usually asymptomatic, more than two third of the cases 
present in an advanced stage. Of all the gynaecological cancer it has the 
highest fatality to case ratio. It is the fifth most common cause of death 
from malignancy in women. 
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Around 75- 80% of ovarian tumors are epithelial in origin. Among 
them, 80% are benign and20% are malignant. Around 80% of malignant 
ovarian tumors arise primarily from ovary, rest of the 20% arise either 
from GIT, breast or colon.              
      
The classification of ovarian tumor (benign and malignant) is 
devised by world health organization according to the most probable 
tissue of origin ( scully 1999) 
1. Surface epithelial (65% -75%) 
2. Germ cell (15%) 
3. Sex cord - stromal (10%) 
4. Metastases (5%)  & miscellaneous 
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SURFACE EPITHELIAL - STROMAL TUMORS 
 
Serous tumors: 
∗ Benign (cystadenoma) 
∗ Borderline tumors (serous borderline tumor) 
∗ Malignant (serous adenocarcinoma) 
 
Mucinous tumors, endocervical-like or intestinal type: 
∗ Benign (cystadenoma) 
∗ Borderline tumors (mucinous borderline tumor) 
∗ Malignant (mucinous adenocarcinoma) 
 
Endometrioid tumors:     
∗ Benign (cystadenoma) 
∗ Borderline tumors (endometrioid borderline tumor) 
∗ Malignant (endometrioid adenocarcinoma) 
 
Clear cell tumors: 
∗ Benign 
∗ Borderline tumors 
∗ Malignant (clear cell adenocarcinoma) 
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Transitional cell tumors: 
∗ Brenner tumor 
∗ Brenner tumor of borderline malignancy 
∗ Malignant Brenner tumor 
∗ Transitional cell carcinoma (non-Brenner type) 
 
Epithelial-stromal 
∗ Adenosarcoma 
∗ Carcinosarcoma (formerly mixed Muellerian tumors) 
 
SEX CORD - STROMAL TUMORS 
 
Granulosa tumors: 
∗ Fibromas 
∗ Fibrothecomas 
∗ Thecomas 
 
Sertoli cell tumors: 
∗ Leydig cell tumors 
∗ Sex cord tumor with annular tubules 
∗ Gynandroblastoma 
∗ Steroid (lipid) cell tumors 
 
39 
 
Germ cell tumors 
Teratoma: 
∗ Immature 
∗ Mature 
∗ Solid 
∗ Cystic (dermoid cyst) 
 
Dysgerminoma 
Endodermal sinus tumor 
Embryonal carcinoma 
Polyembroyoma 
Choriocarcinoma 
Mixed forms 
Monodermal (e.g., struma ovarii, carcinoid) 
Yolk sac tumor (endodermal sinus tumor) 
Mixed germ cell tumors 
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MALIGNANT, NOT OTHERWISE SPECIFIED 
Metastatic cancer from nonovarian primary: 
∗ Colonic, appendiceal 
∗ Gastric 
∗ Breast 
 
SEROUS TUMORS: 
Serous tumors are the most common epithelial ovarian tumor 
constituting 50% of all epithelial tumors. Benign serous tumors 
accounting for approximately 60-70% , while malignant tumors constitute  
20-25% and  borderline constitute 15%.   
 
Serous benign tumors occur in 4th and 5th decade of life. The cyst is 
lined by flattened epithelial cells that resembles fallopian tube lining, 
filled with straw coloured fluid, may have a few coarse papillary 
projections, occur between 30 and 50yrs of age. 
 
Borderline serous tumors occur in 5th decade of life. They have 
finer papillary projections within the cyst cavity.the external surface of 
the tumor also have similar projections. In upto 40% of the patients. 
Similar tumorlets may also found the pelvis and abdominal cavity.5 year 
survival rate is around 70-95%.Recurrences usually develop after 20-
50years in pelvic and abdominal cavity. 
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Malignant tumors are usually multiloculated, partially cystic, and 
may also contain solid areas occur in 6th decade of life. They have an 
abundance of delicate papillary projections. Two third of them are 
bilateral. With stage I tumor, 5 year survival rate is found to be 76% ,56%  
for  stage II ,25% stage III and for patients with stage IV ovarian tumors 
it is around 9%. 
 
MUCINOUS OVARIAN  TUMOR: 
Mucinous tumors are formed by cells that are similar to   intestinal 
or endocervical epithelium. They constitute 15-25% of epithelial ovarian 
tumor. Benign tumors are usually unilateral, multiloculated occurring 
between the third and fifth decade of life. Borderline tumors resembles 
benign tumors but may have solid areas and papillary projections occur in 
fourth and sixth decade of life or more 15-25% of epithelial tumor. They 
are mostly unilateral and usually multiloculated cystic tumor. They may 
reach upto 30cm size. The cyst wall is smooth and filled with thick 
mucinous fluid. Most of them are benign, while 10-15% constitute 
borderline tumor, and 5-10% are malignant. Malignant tumors have more 
papillary projections within the cyst cavities, larger solid areas, larger 
areas of necrosis and haemorrhage. Occur in sixth decade of life. With 
stage I tumor the 5 year survival rate is found to be 83%, and for patients 
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with stage II tumors it is 55%, for stage III it is around 21% and for stage 
IV tumors it is 9%. 
 
Pseudomyxoma peritonei, results from tumor of intestinal type 
which ruptures and leads to dense adhesions. However most cases are 
found to arise from mucinous tumors that are primary to appendix. 
 
ENDOMETRIOD OVARIAN TUMORS: 
These are ovarian tumors formed by cells that resemble 
endometrial lining. They may be associated with endometriosis (15%), 
endometrial hyperplasia, or endometrial carcinoma (20%). 
 
Both Benign and borderline tumors usually occur in 6th decade of 
life and are mostly cystic and unilateral. These tumors have an excellent 
prognosis. 
 
Malignant tumors are predominantly solid and constitutes 80% of 
ovarian endometrioid tumors 10-25% of all ovarian cancer. They have 
better prognosis as compared to serous and mucinous tumors. The 5 year 
survival rate is 78% for stage 1, 63% for stage II tumors, for stage III - 
24% and for stage IV tumors 6%. 
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CLEAR CELL TUMORS: 
Clear cell ovarian tumors, also known as mesonephroid tumor are 
formed by hob nail like cells. Clear cell tumors are usually malignant, 
predominantly solid or cystic with polypoidal mass protruding into them. 
They constitute 4-5% 0f all malignant ovarian tumors, and 50-60% of 
them have endometriosis. They have poorer survival rate when compared 
to other surface epithelial ovarian tumors. 
 
BRENNER TUMOR: 
Brenner, formed by cells that resemble lining of bladder 
(urothelium). It is a rare tumor constituting  2-3% of all epithelial tumors. 
these tumors are usually  small, predominantly solid, and unilateral.  
“Walthard cell nests” is characteristic of Brenner tumor. Due to the 
presence of longitudinal groove these cells have puffed wheat 
appearence. Mucinous tumorare often associated with brenner. 
Occasionally, pseudomeig syndrome presents with Brenner. 
 
GERM CELL TUMORS: 
Germ cell tumors tend to develop in children and adolescents. One 
third of these tumors are malignant. In adults germ cell tumors are rare, 
majority of them being mature cystic teratoma.     
 Teratoma 
 Dysgerminoma 
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 Endodermal sinus tumor(yolk sac tumor) 
 Choriocarcinoma 
They constitute 15-20% of all ovarian tumors, of which 95% of 
them are benign cystic teratoma. 
 
TERATOMA: 
Teratoma are formed by cells derived either from   ectoderm, 
endoderm or mesoderm. It can be mature teratoma (dermoid Cyst), 
Benign Immature teratoma, malignant (Monodermal highly specialised 
tumor – struma ovarii). 
 
Benign cystic teratoma: 
Mature or benign teratomas can be either solid or cystic. Benign 
cystic teratoma is also known dermoid cyst. It is the most common 
ovarian germ cell tumor. Ectodermal cells predominate in most of the 
mature cystic teratoma. They usually have a cyst filled with sebaceous 
material, often have teeth, hair, bone or cartilage. Most commonly occur 
during reproductive years. Rarely they may undergo malignant 
transformation particularly in postmenopausal women.Prognosis is very 
poor with 5 year survival rate being only 15-31%.  
 
These tumors are usually unilateral,grows slowly,but found to be 
large at the time of diagnosis. 
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Immature teratoma: 
They are the second most common germ cell tumor. It is usually 
unilateral,large and predominantly solid. They usually have a malignant 
behavior, grows rapidly, spread by implantation throughout the peritoneal 
cavity. Lymphatic system is the primary channel for metastasis. 
Recurrence occurs following surgey, but combination chemotherapy 
leads to permanent remission. 
 
Struma Ovarii : 
These tumor contain specialised monodermal tissue particularly 
thyroid tissue. Hyperthyroidism occurs in 5-8% of patients with struma 
ovarii. Here the thyroid cells develop at the expense of other tissues. Most 
of them are benign but malignant transformation may occur. 
 
Carcinoid: 
Carcinoid another form of monodermal specialised tumor .It can be 
either primary or secondary. It is also known as Argentaffinoma. It 
secretes hydroxy tryptamine which causes flushing and cyanosis. 
 
DYSGERMINOMA: 
Dysgerminoma is the most common malignant germ cell tumor, 
similar to their testicular counterpart seminoma occurs in 2nd and 3rd 
decade of life. Usually unilateral and 10-20% of them bilateral. 
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These tumors are usually solid, composed of clear round cells. 
They secrete high level of Lactate dehydrogenase and can be used as 
tumor marker. Clear round cells along with lymphocytic infiltration are 
characteristic feature of dysgerminoma. Metastasis occurs in an advanced 
stage of the disease through lymphatic system. These tumors are 
radiosensitive. Prognosis is good with the 5 year survival rate being 100% 
for stage I patients, 75-90% for patients with other stage of the disease. 
However, large tumor, bilaterality,<20years or >20 year are associated 
with poor prognosis. 
 
ENDODERMAL SINUS TUMOR (YOLK SAC TUMOR): 
The cellular structures of these tumors are similar to the primitive 
yolk sac. These are predominantly solid but may have cystic spaces. They 
are highly malignant, invading the surrounding structures. Metastasis 
occur early particularly through lymphatic system. Usually unilateral, 
involvement of the opposite is the evidence of metastasis. Usually secrete 
alpha fetoprotein that can be used as a tumor marker. Radiotherapy is 
ineffective, most cases can be cured with surgery followed by multiagent 
chemotherapy. 
 
EMBRYONAL CELL CARCINOMA: 
Embryonal cell carcinoma is a highly malignant, tend to occur in 
combination with yolk sac tumor. Usually unilateral, solid, large, have 
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variegated appearance occur in children and young adults secrete AFP 
and HCG, and the latter is responsible for precocious puberty and 
abnormal uterine bleeding. Metastasis occurs early through lymphatic   
system. Tumors are radio insensitive, but treatment with surgery and 
chemotherapy cures most of the patients. 
 
CHORIOCARCINOMA: 
Ovarian choriocarcinoma, rare form, formed by placental elements. 
They are usually solid, unilateral and have a haemorrhagic appearance. 
Majority of the primary tumors are not related to pregnancy, some may 
occur after pregnancy, in which case most are metastatic. They secrete 
HCG, hence HCG hormonal assay may be used as a tumor marker. They 
are  invasive locally , and  metastasis  early. Gestational choriocarcinoma 
spread through blood stream   whereas non gestational tumors by 
lymphatic system. 
 
SEX CORD STROMAL TUMOR: 
Sex cord stromal tumor constitutes 8% of all ovarian tumors and 
7% of all malignant ovarian tumors. Endocrine manifestations are often 
associated with these tumors. 
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GRANULOSA CELL TUMOR: 
Granulosa cell tumors are formed by cells derived from germinal 
cells in ovarian follicles. Granulosa cell tumor occur in adult form and 
juvenile form. Adult GCT are partially cystic with blood filled loci, and 
solid areas. Most of them are unilateral, slow growing tumor occur in 
postmenopausal women. Most commonly associated with overproduction 
of ovarian hormones resulting in estrogenic manifestations (endometrial 
hyperplasia, endometrial cancer). Treatment is primarily surgical,            
Juvenile GCT are similar to adult one, constitute only 5% of granulosa 
cell tumor. Majority of them are unilateral, and about half of them occur 
before puberty, resulting in precocious sexual development due to 
production of estrogen from the tumor. surgical excision is curative. 
 
Due to its lipid content it will be yellow or orange in cut section. In 
histopathological examination, cells resemble granulosa cells, with 
characteristic formation of Call Exner body. Coffee bean appearance is 
pathagnomonic of granulosa cell tumor. 
 
The tumor cells also secrete inhibin which can be used as a tumor 
marker. Metastasis first spreads to opposite ovary followed by lumbar 
region then later on to liver, mesentery and the mediastinum. 
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THECA CELL TUMOR: 
Theca cell tumor is a rare, solid tumor formed by theca cells which 
resembles cells that surrounds the ovarian follicles. They are usually 
unilateral, occur in postmenopausal women with the manifestation of 
postmenopausal bleeding, endometrial cancer, endometrial hyperplasia. 
Most of them are benign and surgery is curative. 
 
ARRHENOBLASTOMA: 
These are rare tumors which secretes androgens and cause 
masculinization. Arrhenoblastoma when develops in child bearing age 
group results in alteration of body contour, irregularity of menstruation, 
resulting in amenorrhea. Later, they may develop cliteromegaly, 
hirsutism, and finally with breakup of voice. These tumors are usually 
unilateral with high malignant potential.In HPE, the tumor shows 
seminiferous tubules. 
 
GYNANDROBLASTOMA: 
Gynandroblastoma, is a rare, benign tumor with combination of 
both granulosa cell tumor and arrhenoblastoma. 
 
GONADOBLASTOMA: 
Gonadoblastoma is a rare tumor often associated with 
dysgerminoma. 
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OVARIAN FIBROMA: 
The spindled stromal cells give rise, solid ovarian tumor, fibroma. 
Usually occur after 30 years of age .These tumors often benign and cured 
by surgical treatment. Usually unilateral, rarely bilateral, and may be 
associated with nevoid basal cell carcinoma (also called Gorlin 
syndrome). 
 
Ovarian fibroma is commonly associated with Brenner tumor. 
Ovarian fibroma along with right sided peural effusion and ascites is 
known as meigs syndrome. 
 
METASTASTIC (SECONDARY) CARCINOMA OF OVARY: 
Secondaries of ovary develop with primary elsewhere in the body, 
and they constitute around 20%. Most common of them are from GIT, 
and uterus and cervix. 
 
There are two types of secondary carcinoma. In the first one, the 
secondaries get deposited over the ovary either by direct spread or 
bylymphatic permeation. These tumors are usually bilateral with 
bosselated appearance often associated with ascites and peritoneal 
deposits. 
 
Second one is the Krukenberg tumor. These tumors are often 
bilateral with smooth surface and intact capsule and larger than the 
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primary tumor. Signet ring cell is characteristic of krukenberg tumor 
.Pylorus, colon and breast being the most common primary site. The 
mode of spread is by retrograde lymphatics. 
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                               MATERIALS AND METHODS 
 
This prospective study was performed in the Department of 
Obstetrics and gynaecology, Tirunelveli Medical College and hospital. 
The study was conducted during the period 2012 to 2014.The study 
population consisted of 100 patients who were admitted in our hospital 
with adnexal masses. 
 
 
INCLUSION CRITERIA 
Patients above the age of 25 years admitted in our hospital both in 
premenopausal and postmenopausal age group with a diagnosis of an 
ovarian mass were included in the study. 
 
EXCLUSION CRITERIA 
Ovarian mass in the pregnant women were excluded because CA 
125 levels will be elevated in pregnancy and hence may give a false 
positive result. 
 
Patients with previously diagnosed disease commonly associated 
with elevated CA 125 levels were excluded. Patients on peritoneal 
dialysis which by constant peritoneal irritation cause an elevated CA 125 
levels and are therefore exclude from the study.                
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This study was performed after Institutional ethical committee 
approval. The objective of the study was explained in detail and written 
consent was obtained from the patients included in the study. Serum       
CA 125 and the ultrasound examination were performed at the time of 
preoperative laboratory assessment which was usually accomplished 
approximately within 1 week prior to surgery.  
 
Serum CA 125 was determined by radioimmunoassay.  
 
Ultrasound examination was performed using a 3.5-MHz 
abdominal convex transducer in patients with full bladder or 7.5-MHz 
vaginal probe in patients after empting the bladder. Ultrasound score was 
assigned for the following features. 
1. Multiloculations, 
2. Presence of solid elements, 
3. Bilaterality, 
4. Presence of ascites, or 
5. Evidence of metastases. 
 
An ultrasound score (U) of 1 was given if none or one of the 
features was found, and a score of 3 was given if two or more of these 
features were shown. Postmenopausal status was defined as more than 
one year of amenorrhea or age older than 50 years for women who had 
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undergone  hysterectomy; they were scored as M=3. All other patients 
who did not meet these criteria were defined in a premenopausal status 
which scored M=1. The absolute values of serum CA-125 was entered in 
formula. 
 
Ultrasonographic examination of pelvic organs was performed, 
menopausal status and level of cancer antigen 125 (CA125) were 
assessed and finally RMI was calculated for all the patients. RMI was 
calculated using the formula: 
 
RMI SCORE  =  Ultrasound score x menopausal score x CA125 
    level in U/ml 
 
After surgery, histopathological (HPE) findings of excised tumors 
were analysed in order to determine the final diagnosis. The 
histopathological diagnosis is considered as the gold standard for defining 
the outcomes finally, based on the standard formulas, sensitivity, 
specificity, positive predictive value and negative predictive value of the 
RMI was calculated, as RMI is an index which indicates malignancy with 
reference to the actual presence or absence of malignancy in the ovarian 
mass. 
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SENSITIVITY : 
The sensitivity is defined as the percentage of patients with 
malignant ovarian mass having a positive test result. 
 
Sensitivity = [(true positive / true positive + false negative) × 100] 
 
SPECIFICITY : 
The specificity is defined as the percentage with benign ovarian 
mass showing negative results. 
 
Specificity = [(true negative / true negative + false positive) × 100] 
 
POSITIVE PREDICTIVE VALUE : 
The positive predictive value is defined as the percentage of 
patients with a positive test result having malignant ovarian mass. 
 
Positive predictive value = [(true positive / true positive + false 
positive) × 100] 
 
NEGATIVE PREDICTIVE VALUE : 
The negative predictive value is defined as the percentage of 
patients with a negative test result having benign ovarian mass. 
 
Negative predictive value = [(true negative / true negative + false 
            negative) × 100] 
56 
 
STATISTICAL ANALYSIS : 
Data were analyzed using chi-square tests. Descriptive statistics 
were used for demographic data and summarized as mean with standard 
deviation or frequency with percentage. Univariate analyses to determine 
the association of each parameter were performed using Student’s t test. 
The independent association was then determined by logistic 
regression.The diagnostic performances of each test were reported as 
sensitivity, specificity, positive predictive value, and negative predictive 
value with 95% confidence interval. 
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OBSERVATION & RESULTS 
 
TABLE 1
 
 
HISTOPATHOLOGY NO OF PATIENTS PERCENTAGE 
BENIGN 71 71% 
MALIGNANT 29 29% 
 
 
      The study included 100 patients with ovarian mass of which 71 
patients have benign tumor and 29 patients have malignant ovarian 
tumor. 
 
 
71%
29%
HISTOPATHOLOGY
BENIGN MALIGNANT
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AGE DISTRIBUTION 
 
 <30 30-40 41-50 51-60 >60 
BENIGN (8)10.9% (35)49.3% (17)24.6% (09)12.3% (02)2.7% 
MALIGNANT (0)0 (04)13.7% (09)31% (13)44.8% (03)10.3% 
 
         In the age group of 51-60 yrs of age 44.8% of cases are malignant 
whereas in 30-40 yrs of age only 13.7% are malignant. The percentage of 
malignant ovarian tumor increases with increase in age group. 
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MENSTURAL HISTORY 
 
 BENIGN MALIGNANT 
REGULAR (39)83.30% (09)16.60% 
IRREGULAR (16)80.95% (05)19.04% 
POST MENOPAUSAL (16)54.80% (15)45.10% 
 
    In this study among the postmenopausal women, nearly half of the 
patients have malignant ovarian tumor,16.6% of patients with regular 
cycles and 19%  of the patients  with irregular cycles have malignant 
ovarian tumor. 
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 HPE REGULAR IRREGULAR 
POST 
MENOPAUSAL 
BENIGN (39)54% (16)22.90% (16)22.90% 
MALIGNANT (09)31% (05)17.24% (15)51% 
 
    
         In this study, among the patients with malignant ovarian tumor n=29, 
51% of the patients belong to postmenopausal age group whereas 22.90% of 
the women with benign tumor are in postmenopausal age group. 
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 PRE MENOPAUSAL REGULAR IRREGULAR 
BENIGN (39)70% (16)29.82% 
MALIGNANT (09)6.60% (05)33.30% 
 
Among 69 patients in premenopausal age group  70% of patients 
with benign tumor  have regular cycles whereas the remaining have 
irregular cycles .6.6% of patients with malignant ovarian tumor have 
regular cycles and 33.3% have irregular cycles . 
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PARITY INDEX 
 
PARITY INDEX BENIGN,(n) % MALIGNANT,(n)% 
NULLIPAROUS (08)53% (07)46.60% 
MULTIPAROUS (63)75% (22)24.70% 
 
  In our study 15 patients are nulliparous and   85 patients   are 
multiparous women. In nulliparous women 53% have benign ovarian 
tumor, whereas 46% have malignant ovarian tumor .Among multiparous 
women 75% have benign and 24% have malignant ovarian tumor. 
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 HPE NULLIPAROUS MULTIPAROUS 
BENIGN (8)10% (63)90.14% 
MALIGNANT (7)24.13% (22)75.86% 
 
Among the patients with benign tumors, 10% are nulliparous and 
90% are multiparous and among patients with malignant tumors 24% are 
nulliparous and 75.86% are multiparous. 
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MENOPAUSAL STATUS 
 
 BENIGN MALIGNANT 
PREMENOPAUSAL (55)82.60% (14)17.39% 
POSTMENOAPUSAL (16)54.83% (15)45.16% 
       
In our study 69 patients are in premenopausal age group and   31 
patients are in postmenopausal age group. Among    69   premenopausal 
patients 55   have   benign tumor accounting for 82.6% and 14 have 
malignant tumor accounting for 17.39%. Among 31 postmenopausal 
patients 16 have benign tumor accounting for 54.83% and 15 patients 
have malignant ovarian tumor accounting for 45.16% 
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 HPE PREMENOPAUSAL POSTMENOAPUSAL 
BENIGN (55)77.02% (16)22.97% 
MALIGNANT (14)46.15% (15)53.84% 
 
Among 71 benign tumors, 77.02% of patients are in premenopausal 
age group and 22.97% in postmenopausal age group .Among 29 patients 
with malignant tumors 46.15% are in premenopausal age group and 
53.84% are in postmenopausal age group. Sensitivity, specificity, positive 
predictive value and negative predictive value of menopausal score are 
53.84%,77.02% ,45.61% and,82.61%, respectively. 
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USG SCORE BENIGN MALIGNANT 
USG SCORE 1 (52)82.53% (11)17.46% 
USG SCORE 3 (19)51.35% (18)48.64% 
 
In this study, 63 Patients have ultrasound score of 1, that is 
presence of one or none of the parameters in ultrasound. Among 63   
patients, 82.53% have benign lesions and 17.46% patients have malignant 
ovarian tumor.  27 patients have ultrasound score of 3 indicating presence 
of   2 or more parameters of ultrasound criteria. Among   Patients with 
ultrasound score of 3, 51.35% have benign lesions and 48.64% have 
malignant ovarian tumor .   
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On analysis, among benign tumors 73.23% have ultrasound score 
of 1 and 26.76% have ultrasound score of 3. Among malignant ovarian 
tumor 37.93% have ultrasound score of 1 and 62% have ultrasound score 
of 3. 
 
The performance status of ultrasound score has been analysed with 
sensitivity of 62.06%, specificity of 73.23%,positive predictive value of 
48.64% and negative predictive value of 82.54% respectively. 
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HPE USG SCORE 1 USG SCORE 3 
BENIGN (52)73.23% (19)26.76% 
MALIGNANT (11)37.93% (18)62.06% 
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CA 125-CUT OFF 35 
 
CA125 BENIGN MALIGNANT 
< 35 (50)92.72% (05)7.27% 
>35 (21)48.88% (24)51.11% 
 
        CA 125 is analysed with cut off value of 35U/ml. Normal range is 0-
35U/ml. In our study, CA 125 with cut off value of 35U/ml 45 patients 
have   >35U/ml. 
 
Among them 48% have benign lesions and 51% have malignant 
lesions.  92.72% of patients with CA 125 <35U/ml have benign lesions 
and 7.27% have malignant lesions. 
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HPE < 35 >35 
BENIGN (40)69.86% (31)30.13% 
MALIGNANT (05)14.81% (24)85.18% 
 
 
SENSITIVITY-85.18% 
SPECIFICITY-69.86% 
POSITIVE PREDICTIVE VALUE -51.11% 
NEGATIVE PREDICTIVE VALUE-92.73% 
 
 
          Among patients with benign tumor, 69.85% have CA 125< 35U/ml 
and 30.13% have CA 125 > 35U/ml whereas the patients with malignant 
ovarian tumor 14.8% have CA 125 <35 and 85.18% have CA 125 
>35U/ml.  
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RMI- CUT OFF 100 
 
RMI CUT OFF 100 BENIGN MALIGNANT 
<100 (59)95.16% (03)4.83% 
>100 (12)34.21% (26)65.78% 
 
       
 The risk of malignancy index based on USG score, CA -125 and 
menopausal status was calculated preoperatively. With the cut off value 
of 100, 62 patients are below 100 and  38 patients are above 100. 95.16% 
of patient with RMI <100 have benign tumor and   65.78% of patients 
with RMI >100 have malignant tumor. 81.94% of patients with benign 
tumor have RMI <100 and 89.24% of patients with malignant tumor have 
RMI > 100.       
 
 
The sensitivity of RMI with cut off point of 100 is 89.24%, 
specificity is 81.94%, positive predictive value is 65.79% and negative 
predictive value is 95.16%. 
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 RMI - CUT OFF 150 
 
 
RMI BENIGN MALIGNANT 
<150 (65)92.85% (06)7.14% 
>150 (06)23.33% (23)76.66% 
 
 
With the cut off value of RMI at 150, 71 patients have value   
below 150 and 29 patients have value above 150. Patients with RMI 
<150, 92.85% have benign lesions and 7.14% have malignant lesions. 
Those with RMI > 150, 23.33% have benign lesions and 76.66% have 
malignant lesions 7.14% of patients with benign tumors have RMI <150 
and 76.66% of patients with malignant tumors have RMI >150. 
 
         With the cut off value of 150, sensitivity, specificity, positive 
predictive value and negative predictive value are S 80%, 87.7%, 65.5% 
and 93.8% respectively. 
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 RMI CUT OFF 200 
 
RMI CUT OFF 200 BENIGN MALIGNANT 
<200 (68)93.15% (05)6.84% 
>200 (03)14.81% (24)85.18% 
 
In this study 73 patients have RMI value <200 and 27 patients have 
RMI >200. 93.15% and 6.84% of patients with RMI < 200 have benign 
and malignant tumor respectively .Those with RMI >200, 14.81% have 
benign lesions and 85.18% have malignant tumors. 
 
The sensitivity of RMI with cut off value 200 is 82.14%, 
specificity is 94.44%, positive predictive value is 85.19%, negative 
predictive value is 93.15%. 
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 RMI CUT OFF 250 
 
RMI CUT OFF 250 BENIGN MALIGNANT 
<250 (68)93.24% (05)6.75% 
>250 (03)15.38% (24)84.61% 
      
 
If the RMI has the cut off value of 250, 73 patients have RMI <250 
and 27 patients have RMI > 250. 93.24 % of patients with RMI <250 
have benign lesion and 6.75% have malignant lesions.15.38% of    
patients with RMI> 250 have benign lesions and 84.61% of patients   
have malignant lesions. 
 
 
With the cut off value of 250 sensitivity, specificity ,positive 
predictive value and negative predictive value are 81.48%, 94.52%, 
84.62% and 93.24% respectively. 
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COMPARISON OF RMI 
 
 
RMI SENSITIVITY SPECIFICITY PPV NPV 
100 89.24% 81.94% 65.79% 95.16% 
150 82.14% 90.28% 76.67% 92.86% 
200 82.14% 94.44% 85.19% 93.15% 
250 81.48% 94.52% 84.62% 93.24% 
 
The sensitivity of the RMI in discriminating benign and malignant 
ovarian tumor is high with the cut off value of 100. The sensitivity 
decreases as the cut off value of RMI is increased. The specificity of RMI 
is high with the cut off value of 250. Specificity increases with increase in 
the cut off value of RMI. Likewise the positive predictive value increases 
with increase in the cut off value of RMI. The positive predictive value is 
high at the cut off value of 250. The negative predictive value decreases 
with increase in the cut off value of RMI. The negative predictive value is 
high at the cut off value of 100. The optimal sensitivity, specificity, 
positive predictive value and negative predictive value for RMI is high at 
the cutoff value of 200.The cut off value of RMI at 200 is highly 
statistically significant, associated with the gold standard (HPE) i.e. 
malignant or benign. 
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 COMPARISON OF VARIOUS PARAMETERS: 
 
 SENSITIVITY SPECIFICITY PPV NPV 
PARITY 11.10% 75% 53.33% 24.71% 
MENOPAUSAL 
SCORE 
53.84% 77.02% 45.6% 82.61% 
USG SCORE 62.07% 73.23% 48.64% 82.54% 
CA 125 85.18% 69.86% 51.11% 92.73% 
RMI 82.14% 94.44% 85.19% 93.24% 
 
The sensitivity of parity as a diagnostic indicator is low %, 11.1% 
the specificity is high 75%, the positive predictive value is 53.33% and 
negative predictive value is 24.71% .  
 
         The diagnostic performance of sensitivity of menopausal score 
is 53.84%, specificity is 77.02%, positive predictive value is 45.61% and 
negative predictive value is  82.61%. Thus menopausal score has high 
 Specificity and   negative predictive value. 
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       The sensitivity of ultrasound score as diagnostic modality in 
differentiating benign and malignant tumor is 62.06%, specificity is 
73.23%, positive predictive value is 48.64% and negative predictive value 
is 82.54%. The specificity and negative predictive value are high for 
ultrasound score.         
 
The sensitivity of CA 125 with a cut off value of 35 U/ml is 
85.18%, specificity is 69.86%, positive predictive value is 51.11% and 
negative predictive value is 92.73%. CA 125 has high sensitivity   and 
negative predictive value. 
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       The diagnostic performance of sensitivity, specificity, positive 
predictive value and negative predictive value of RMI at cut off value of 
200 are 82.14%, 94.42%, 85.19% and 93.15% respectively. 
 
      We found that RMI has better performance than CA 125, ultrasound 
score and   menopausal score. 
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BENIGN TUMORS 
 
S.NO HISTOPATHOLOGY 
NO.OF 
PATIENTS 
% OF 
BENIGN 
TUMORS 
%  OF 
TOTAL 
1 MCA 09 12.67 9 
2 SCA 29 40.84 29 
3 DERMOID 08 11.26 8 
4 SIMPLE SEROUS CYST 16 22.53 16 
5 
CORPUS LUTEAL 
CYST 
03 4.22 3 
6 FOLLICULAR CYST 02 2.81 2 
7 
ENDOMETRIOTIC 
CYST 
03 4.22 3 
8 
LUTEINISED 
THECOMA 
01 1.40 1 
 
In this study serous cystadenoma is the most common tumor 
accounting 29% of the total tumor and 40.84% of the benign 
tumor.Simple serous cyst is the second most common which constitutes 
16% of the total and 22.53% of the benign tumor.Next most common 
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tumor is the mucinous cystadenoma accounting for 9% of the total and 
12.67% of the benign tumors. 
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 MALIGNANT TUMORS 
 
S.NO HISTOPATHOLOGY 
NO.OF 
PATIENTS 
% OF 
MALIGNANT 
TUMORS 
% OF 
TOTAL 
1 SCC 18 62.06 18 
2 MCC 02 6.89 2 
3 
GRANULOSA CELL 
TUMOR 
01 3.44 1 
4 
BODERLINE 
MUCINOUS 
01 3.44 1 
5 KRUKENBERG 01 3.44 1 
6 CLEAR CELL CA 01 3.44 1 
7 GERM CELL TUMOR 01 3.44 1 
8 
ENDOMETRIOD 
ADENOCA 
03 10.34 3 
9 DYSGERMINOMA 01 3.44 1 
          
In our study, the most common malignant tumor is papillary serous 
cystadenocarcinoma comprising 62.06% of patients with malignant 
cancer. It accounts for 18% of total patients. The second common 
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malignant tumor is mucinous  cystadenocarcinoma  accounting for 6.89% 
of malignant cases and 4.5% of total cases. The next tumors are 
endometrioid carcinoma accounting for 10.34% of malignant ovarian 
tumor. 
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                                                DISCUSSION 
 
           In our study, the peak incidence of the malignant ovarian tumor 
was 51-60 years of age during which 44.6% of ovarian tumors were 
malignant. The study shows that among those less than 40 years of age 
group, most of the neoplasms were benign and as age increases the risk of 
malignancy increases. 
 
        Various case control studies have shown that pregnancy reduces  the 
risk of ovarian cancer. One pregnancy reduces the risk of ovarian  cancer 
by as much as one third and with subsequent preganancies the   risk 
lowers further. Infertility has an increased risk of ovarian   malignancy 
around 2 fold. In our study the ovarian mass among  nulliparous women 
had more incidence of malignancy when compared   to multiparous 
women. The study showed among nulliparous women 46.6% had 
malignant tumors compared to 24.7% in multiparous women. 
 
             On analysing the menstrual history, nearly half of the 
postmenopausal women had malignant ovarian tumor. Among 
menstruating women there was a slightly higher chance of malignancy in 
those with regular cycles when compared to patients with irregular cycle. 
 
         The study showed that the patients who had malignant ovarian  
neoplasm, most of them were in the postmenopausal status. 45.16% of    
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postmenopausal women had malignancy when compared to 17.39% in 
premenopausal women. Thus in postmenopausal women the malignant 
neoplasms are more common. 
 
          Sonographic evaluation of the structure of an ovarian mass in 
predicting the risk of malignancy have been reported. Many  investigators 
have developed the objective Ultrasound score according  to various 
ovarian morphologies to minimize the examiners descriptive 
interpretation which may be varied and not reproducible. 
 
          Many scoring systems based on various ultrasonographic  
morphologies have been made for this purpose. These scoring  
morphologies are tumor volume, number of locularities, wall  thickness, 
inner wall structure, septal structure, and shadowing or   echogenicity or 
solid area . At different cut-off levels of Ultrasound scores as an indicator 
for discrimination of benign from malignant tumors, the sensitivity, 
specificity, positive predictive value (PPV) and  a negative predictive 
value (NPV) from these studies ranged from 74- 88%, 40-65%, 28-36%, 
and 90-95%, respectively. Ferrazzi et al [45]., in1997, developed the new 
multicenter scoring system in determination of malignancy status of 
ovarian tumors based on the  ultrasound morphology of the ovarian cyst 
wall, septae, vegetations,and echogenicity. The new scoring system 
yielded better result than the previous scoring systems reported in the 
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other studies with the accuracy, sensitivity, specificity, positive predictive 
value and negative predictive value of 72%, 87%, 67%, 41% and 95%, 
respectively. 
 
For ultrasonographic technique in diagnosing ovarian cancer  the 
sensitivity was 62% and specificity was 73% as shown in various  study 
including Morgante et al(30)  1999, Leelahakorn et al (29) 2005. 
 
In our study, the sensitivity of ultrasonographic score was 62.06% 
and specificity was 73.23%, the positive predictive value was 48.64% and 
negative predictive value was 82.94%. 
 
The study showed that ultrasonogram of complex ovarian mass has 
more malignant potential. All though the value of CA 125 as a screening 
test for ovarian cancer is yet unsettled, its role for a differential diagnosis 
of ovarian mass is clearly established. CA125 a tumor marker for ovarian 
cancer is not specific. With a cut off value of 35 U/ml, 
 
 True positive – 24 cases 
 True negative – 40 cases 
 False positive – 31 cases 
 False negative – 5 cases 
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           Among the five false negative cases, 2 cases were germ cell 
Tumor, one was granulosa cell tumor, one was krukenberg, and another 
one was serous cystadenocarcinoma. 
 
     Among 31 false positive cases, 24 cases were serous cystadenoma, 5 
cases were mucinous cystadenoma. 
 
CA 125 level has overall range of 6.7 - 832.64.The high values of 
CA 125 is found most commonly with papillary serous 
cystadenocarcinoma and endometrioid adenocarcinoma. 
 
Benjapi bal et al [44], 2007 showed that CA 125 at the cut off level 
of 35 U/ml had the sensitivity of 83.1% and specificity of 39.3%. In 
2010, Rachmasari putri et al study showed that CA 125 level at a cut off 
value of 35 U/ml had a sensitivity of 81.43% and specificity of 60%, 
positive predictive value of 87.69% and negative predictive value of 48%. 
 
In our study, the sensitivity was 85.18% and the specificity was 
69.85% the positive predictive value and the negative predictive value 
were 92.73% and 51.11% respectively. Our study showed that CA 125 
has high sensitivity and high positive predictive value. The specificity 
was poor in predicting malignancy. 
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RMI was calculated using the formula for each patient included in 
the study (n=200). Out of 100 patients, the RMI with cut off value of 200, 
68  patients had benign tumor and 24 patients had malignant   tumor. 
 
 True positive - 24 cases 
 True negative -68  cases 
 False positive -3  cases 
 False negative - 5 cases 
 
5 patients with RMI less than 200 had malignant ovarian cancer 
constituting false negative (6.8%). Out of 5 patients, 2 patients had germ 
cell tumor and 1 patients had  mucinous   cystadenocarcinoma, 1 had 
krukenberg  and another one patient had granulosa cell tumor. 
 
Among the 27 patients with RMI >200, 3   had benign tumors 
constituting the 14.81% of false positive cases. Out of 3 patients, 2 
patients had serous cystadenoma and 1 patient had mucinous 
cystadenoma. 
 
Thus serous cystadenoma was the most common cause of false 
positivity and germ cell tumor was the most common cause for false 
negativity. 
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The false positive rates are important when a particular test has to 
be used in low risk populations diagnosed with ovarian mass during 
screening of ovarian abnormalities. 
 
Among the benign tumors, the RMI had a range from 6.7 to 
865.35.The mean RMI was 81.55 with SD 133.31. Among the malignant 
tumors the range is from 28.92 to 7493.76. The average RMI was 
1158.44 with SD 1752.13. This was statistically significant. 
 
In our study, the performance of sensitivity, specificity, positive 
predictive value and negative predictive value of RMI at various cutoff 
levels of 100,150, 200, 250, were analysed. At a cut off level of 100, the 
RMI had highest sensitivity (89.24%) and negative predictive value 
(95.16%).The specificity (81.94%) and positive predictive value 
(65.79%) were low. As the cut off levels are increased, the sensitivity 
decreases and specificity increases. RMI at cut off value of 250, has the 
highest specificity (94.52%) and positive predictive value (84.62%). The 
sensitivity was low 81.48%. Multiple studies have shown that the best cut 
off value of RMI is 200. In our study, the performance of RMI at 200 is 
statistically significant as shown by the sensitivity 82.14%, specificity 
94.4%, positive predictive value 85.19% and negative predictive value 
93.15%. 
 
96 
 
 COMPARISON OF VARIOUS PREVIOUS STUDY WITH THE 
PRESENT STUDY 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
PRESENT STUDY 2013 100 82.14% 94.4% 85.19% 93.15% 
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SUMMARY 
 
 100 women with ovarian mass above 25 years of age were selected 
for the study. Patients with pregnancy are excluded. 
 
 44.8% patients were in the age group of 51- 60 years,31% in 41 – 
50 years,13.7% in 30 - 40 years and 10.3% in >60 years. 
 
 General and gynaecological examination was done for all cases. 
 
 Ultrasound pelvis was done for all patients and the presence of 
bilateral ovarian mass, multiloculated  tumor, presence of solid  
areas, ascites and extra ovarian metastasis were noted. An 
ultrasound score (U) of 1 was given if none or one of the features 
was found, and a score of 3 was given if two or more of these 
features were shown. 
 
 Serum CA 125 level was measured preoperatively. 
 
 Postmenopausal status was defined as more than one year of 
amenorrhea or age older than 50 years for women who had 
undergone hysterectomy; they were scored as M=3. All other 
patients who did not meet these criteria were defined in a 
premenopausal status which scored M=1. 
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 Risk of malignancy index was calculated based on RMI 3 
(modified by Tingulstad [20] in 1999). 
 
 Laparotomy was done for all cases and the specimen was sent for 
histopathological examination which is the gold standard. 
 
 79% of the tumor was benign and 21% was malignant. 
 
 Prediction of malignancy by CA 125, ultrasound and RMI was 
compared and analysed. 
 
 The optimal sensitivity, specificity, positive predictive value and 
negative predictive value for RMI were at the cut off value of 200. 
 
 The diagnostic performance of sensitivity, specificity, positive 
predictive value and negative predictive value of RMI at cut off 
value of 200 were 82.14%, 94.44%, 85.19% and 93.15% 
respectively. 
 
 Though CA 125 was highly sensitive (sensitivity was 85.18%), 
specificity and PPV were poor. 
 
 The study showed that RMI has the better performance than CA 
125, ultrasound score and menopausal score in the prediction of 
malignancy. 
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CONCLUSION 
 
Risk of malignancy index is a reliable method for differentiating 
benign and malignant ovarian mass preoperatively. 
 
Risk of malignancy index is a multimodal approach that is simple 
and easily applicable in preoperative evaluation of patients with ovarian 
tumor. 
 
Risk of malignancy index is a better diagnostic scoring index in 
discriminating benign and malignant tumor when compared to individual 
test of ultrasonogram or CA 125 level. 
 
The optimal cut off point that best distinguishes benign from 
malignant ovarian mass for RMI is 200 in the present study. 
 
RMI is the most useful diagnostic index in proper selection of 
patients who may require referral to tertiary care centers. 
 
Since the specificity of Risk of malignancy index is high, there is a 
potential role for this index in selection of cases for conservative 
management or minimal invasive surgery of benign cases like ultrasound 
guided aspiration or laparoscopic excision of the cysts. 
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PROFORMA 
 
NAME :                            AGE :                                 IP NO : 
SE CLASS :                                                               RELIGION : 
PRESENTING ILLNESS :  MASS 
                                           DURATION   
                                          PAIN ABDOMEN 
                                           ABD DISTENSION 
MENSTRUAL HISTORY : 
MENOPAUSE :             YES                NO 
MARRIED   : YES          NO                                NO.OF YEARS: 
OBSTETRIC HISTORY :                                      NULLIPAROUS 
PAROUS 
NOC 
LCB 
OVULATION INDUCTION 
CONTRACEPTION : YES                    NO 
OCP 
ST 
OTHERS 
PAST MEDICAL HISTORY : DM/HT/IHD/TB/ 
SURGICAL HISTORY : YES                       NO 
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FAMILY HISTORY :  
                   OVARIAN MALIGNANCY 
                   ENDOMETRIAL CA 
                   BREAST CA. 
GENERAL EXAMINATION : 
                                     HEIGHT: 
                                     WEIGHT: 
                                             BMI: 
                                             O/E :ANAEMIA 
                                                    PEDAL EDEMA 
                                                    LYMPH NODES 
                                    BREAST 
                                   THYROID 
                                   VITAL SIGNS: PR 
                                                           BP 
                                   P/A :  
                                       MASS 
                                      ASCITES 
                                      OTHERS 
                  P/S 
                  P/V 
USG ABDOMEN & PELVIS  
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S.NO USG FEATURES PRESENT ABSENT 
1 MULTISEPTATIONS   
2 SOLID COMPONENTS   
3 BILATERALITY   
4 ASCITES   
5 METASTASIS   
                 
ULTRASOUND SCORE : 
CA 125 VALUE : 
MENOPAUSAL SCORE : 
RISK OF MALIGNANCY INDEX : 
LAPAROTOMY FINDINGS 
HPE 
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                                  CONSENT FORM 
 
STUDY TITLE :  
STUDY OF RISK OF MALIGNANCY INDEX WITH 
HISTOPATHOLOGICAL EXAMINTION IN OVARIAN TUMORS. 
 
STUDY CENTRE :  
Department of Obstetrics and Gynaecology, Tirunelveli Medical 
College And Hospital, Tirunelveli. 
 
Participant Name:         Age:               Sex:               I.D.No.: 
 
I confirm that I have understood the purpose of the above study. I 
have the opportunity to ask the questions and all my questions and doubts 
have been answered to my satisfaction. 
 
I understand that my participation in the study is voluntary and that 
I am free to withdraw at any time without giving any reason. 
 
 I understand that the investigator, regularity authorities and the 
ethics committee will not need my permission to look at my health 
records both in respect to the current study and any further research that 
may be conducted in relation to it, even if I withdraw from the study. I 
understand that my identity will not be revealed in any information 
released to third parties of published, unless as required under the law. 
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I agree not to restrict the use of any results that arise from the 
study. I hereby consent to participate in this study titled “STUDY OF 
RISK OF MALIGNANCY INDEX WITH HISTOPATHOLOGICAL 
EXAMINATION IN OVARIAN TUMORS” 
 
Signature of Investigator: 
 
Study Investigators Name: 
 
Signature/thumb impression of patient 
 
Date :                                                                                    Thanking you, 
Place : 
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BENIGN 
 MUCINOUS CYSTADENOMA(MCA)-9 
 SEROUS  CYSTADENOMA(SCA)-29 
 DERMOID-8 
 SIMPLE SEROUS CYST-16 
 CORPUS LUTEAL CYST-3 
 FOLLICULAR CYST-2 
 ENDOMETRIOTIC CYST-3 
 LUTEINISED THECOMA-1 
 TOTAL-71 
 
MALIGNANT 
 SEROUS CYSTADENOMA CARCINOMA(SCC)-18 
 MUCINOUS CYSTADENOCARCINOMA(MCC)-2 
 GRANULOSA CELL TUMOR-1 
 BORDERLINE MUCINOUS-1 
 KRUKENBERG-1 
 CLEAR CELL CA-1 
 GERM CELL TUMOR-1 
 ENDOMETRIOID ADENOCA-3 
 DYSGERMINOMA-1 
 TOTAL-29 
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KEY TO THE MASTER CHART 
RMI   -  Risk of Malignancy Index 
USG   -  Ultrasonogram 
NG   -  NulliGravida 
REG   -  Regular 
IRREG  -  Irregular 
PMB   -  Post Menopausal Bleeding 
ABD   -  Abdomen 
MNP   -  Menopause 
P   -  Para 
L   -  Live 
A   -  Abortion 
ST   -  Sterlised 
HPE   -  Histopathological Examination 
SCA   -  Serous Cystadenoma 
MCA  -  Mucinous Cystadenoma 
PSCC  -  Papillary Serous Cystadeno Carcinoma 
MCC   -  Mucinous Cystadeno Carcinoma 
SCC   -  Serous Cystadeno Carcinoma 
GCT   -  Granulosa Cell Tumor 
EAC   -  Endometroid Adeno Carcinoma 
MNP   -  Menopausal 
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MENSTRUAL USG
HISTORY SCORE
1 1 MARIYAPUSHPAM 55 23882 ABD.DISTENSION MNP-8 P4L4/ST 3 1 19 57 MCA
2 2 LINGAMMAL 55 55314 ABD PAIN MNP-7 P4L3/ST 3 3 312.6 2813.4 SCC
3 3 SELVI 50 23451 ABD.DISTENSION MNP-4 P4L3 3 1 42 126 KRUKENBERG
4 4 PUTHIYAL 55 54674 ABD.DISTENSION MNP-6 P3L2 3 1 10.5 31.5 SIMPLE SEROUS CYST 
5 5 MUTHAMMAL 50 17800 ABD.DISTENSION MNP-4 P4L3 3 1 9.8 29.4 SCA
6 6 DRAVIDASELVI 48 15099 PAIN RG P3L3 1 1 6.9 6.9 SIMPLE SEROUS CYST
7 7 MUTHUMARI 30 17112 ABD.DISTENSION P2L2 1 1 6.7 6.7 MCA
8 8 DEIVANAI 65 28909 ABD PAIN , ABD.DISTENSION MNP-12 P7L7 3 1 750 2250 SCC
9 9 SELVARANI 39 26366 ABD PAIN RG P2L2/ST 1 1 18.6 18.6 SCA
10 10 DHANALAKSHMI 49 22535 ABD PAIN IRRG P3L3 1 3 198.4 595.2 SCC
11 11 PUSHPAM 55 22181  ABD PAIN MNP-7 P1L0 3 3 878.3 7904.7 SCC
12 12 DEIVANAI 57 14411 MNP-5 P5L5 3 3 75.6 680.4 MUCINOUS BORDERLE TUMOR
13 13 MUTHURAMAYEE 48 55698 ABD PAIN MNP-2 P3L2 3 3 8.5 76.5 SIMPLE SREOUS CYST
14 14 KASTHURI 55 53940 ABD PAIN, ABD.DISTENSION MNP-4 NP 3 3 600 5400 SCC
15 15 MUTHUSELVI 26 34256 ABD PAIN RG P2L2 1 1 27 27 CORPUS LUTEAL CYST
16 16 VIJAYALAKSHMI 32 16170 ABD.DISTENSION IRRG P2L2 1 1 9 9 MCA
17 17 MADATHY 65 15068 ABD.DISTENSION RG P4L4 3 3 600 5400 SCC
18 18 VASANTHA 40 18890 ABD.DISTENSION RG P2L2 1 3 184.2 552.6 CLEAR CELL CA
19 19 VIJAYALAKSHMI 32 16170 ABD.DISTENSION RG P2L2 1 1 9 9 SIMPLE SEROUS CYST
20 20 SHANMUGAM 42 13468 ABD PAIN MNP-2 P3L3 1 1 123 123 SCA
21 21 BALASUBBULAKSHMI 21 6677 ABD.DISTENSION RG NP 1 1 17 17 SCA
22 22 ESAKKIAMMAL 30 51418 ABD PAIN , ABD.DISTENSION RG NP 1 1 956.2 956.2 ENDOMETRIOID ADENOCA
23 23 KUTTITHAI 55 49856 ABD PAIN MNP-6 P4L4 3 3 177.5 1597.5 SCC
24 24 RAJAMUNISHA 20 10732 ABD PAIN RG NP 1 1 14.1 14.1 FOLLICULAR CYST
25 25 CHELLAMMAL 58 28164 ABD PAIN MNP-9 P7L6 3 1 415.5 1246.5 MCC
26 26 MAHALAKSHMI 58 40803 ABD.DISTENSION MNP-9 P4L3 3 3 32 288 MCA
27 27 MALAYAMMAL 49 45632 ABD.DISTENSION MNP-2 P3L2 3 1 3000 9000 SCC
28 28 RAJAMMAL 41 13456 ABD PAIN RG P2L2 1 1 946 946 SCC
29 29 KASTHURI 55 53940 ABD PAIN , ABD.DISTENSION MNP-6 NP 3 1 6000 18000 SCC
30 30 SUBBAMMAL 68 56701 ABD PAIN MNP-16 P10L6 3 1 29 87 SCA
31 31 APARNA 14 13643 ABD.DISTENSION IRRG NP 1 1 9.9 9.9 SIMPLE SEROUS CYST
MENOPAUSAL 
SCORE CA 125 RMI SCORE HPE
S. 
NO NAME AGE IP NO COMPLAINTS PARITYSl.No
32 32 JEYAVALLI 30 45103 ABD PAIN RG P3L3 1 1 13 13 DERMOID
33 33 ESAKKIAMMAL 36 70798 ABD PAIN RG NP 1 3 48 144 SCA
34 34 VAIRAMUTHU 45 51216 ABD PAIN RG P2L2 1 3 10.6 31.8 DERMOID
35 35 LAKSHMI 41 52929 ABD PAIN IRRG P3L3 1 3 19.42 19.42 MCA
36 36 PUNITHAMALAR 34 10884 ABD PAIN RG P3L3/ST 1 1 15.8 15.8 SIMPLE SEROUS CYST
37 37 SUBBALAKSHMI 36 8750 ABD PAIN RG P2L2/ST 1 1 13 13 SIMPLE SEROUS CYST
38 38 LATHA 45 3124 ABD DISTENTION IRRG P3L3/ST 1 3 198.74 596.22 SCC
39 39 SAKUNTHALA 45 5673 ABD.DISTENSION RG P3L3/ST 1 3 64.1 192.3 SCA
40 40 RAMALAKSHMI 54 14193 PAIN , ABD.DISTENSION MNP-6 P3L3/ST 3 3 60.1 540.9 SCA
41 41 THANGAM 52 15756 ABD.DISTENSION MNP-4 P3L3 3 3 19.42 174.78 MCA
42 42 CHANDRA 45 19529 ABD.DISTENSION REG P2L2/ST 1 3 9.35 28.05 DERMOID
43 43 KANNIAMMAL 32 23911 ABD PAIN REG P2L1A2 1 1 64.16 64.16 SCA
44 44 MAHALAKSHMI 35 27577 ABD PAIN IRREG P2L2/ST 1 1 69.49 69.49 SCA
45 45 PAKKIYATHAI 40 25804 ABD PAIN REG P2L2 1 1 10.67 10.67 SIMPLE SEROUS CYST
46 46 LAKSHMI 50 28683 ABD.DISTENSION MNP-4 P4L2/ST 3 3 56.92 512.28 SCC
47 47 MUTHAMMAL 55 27570 PAIN MNP-2 P2L2/ST 3 1 10.9 32.7 GRANULOSA CELL TUMOR
48 48 THAMBIRATTI 53 27091 ABD.DISTENTION MNP-4 P4L2/ST 3 3 56.92 512.28 SCC
49 49 KALAIMATHI 51 30565 ABD PAIN REG P2L2 1 1 10.67 10.67 SIMPLE SEROUS CYST
50 50 PANEER 40 30297 ABD PAIN  RG P1L1 1 3 26.9 80.7 DERMOID
51 51 VIJAYA 34 55261 ABD PAIN RG P1L2 1 1 11.5 11.5 DERMOID
52 52 PETCHIAMMAL 49 58221 ABD DISTENSION IRRG P4L2/ST 1 3 727.18 2181.54 EAC
53 53 BANUPRIYA 15 45632 ABD PAIN RG P3L3/ST 1 1 16.86 16.86 SIMPLE SEROUS CYST 
54 54 MUTHULAKSHMI 25 53078 ABD PAIN RG P2L2 1 1 6.7 6.7 SIMPLE SEROUS CYST
55 55 MUPPIDATHY 30 54653 ABD PAIN RG P2L2/ST 1 1 9.03 9.03 DERMOID
56 56 MUPPIDATHY 32 56585 ABD PAIN IRRG NP 1 1 7.12 7.12 ENDOMETRIOTIC CYST
57 57 SUDHA 36 59466 ABD PAIN RG P3L3/ST 1 3 59.37 178.11 SCA
58 58 MARY 23 22319 ABD PAIN RG P2L2 1 1 7.3 7.3 SIMPLE SEROUS CYST
59 59 MUPPIDATHY 32 57131 ABD DISTENSION RG P2L2 1 3 8.2 24.6 DYSGERMINOMA
60 60 MARIAMMAL 45 57656 ABD PAIN RG P2L2 1 3 49.35 148.05 SCA
61 61 BOMMUAMMAL 65 60220 ABD PAIN RG P3L3 1 3 81.8 245.4 SCA
62 62 MARIAMMAL 39 59146 ABD PAIN RG P3L2 1 1 87.19 87.19 SCA
63 63 MARIAMMAL 38 58968 ABD PAIN IRRG P2L2 1 1 5.6 5.6  CORPUS LUTEAL CYST
64 64 SUSILA 42 63388 ABD DISTENTION RG P4L2/ST 1 3 731.84 2195.5 ENDOMETRIOID ADENO CA
65 65 MARIAMMAL 52 66537 ABD DISTENTION MNP-6 NP 3 1 101.41 304.23 SCC
66 66 LAKSHMI 61 66211 ABD PAIN MNP-1 P2L2/ST 3 1 9.64 28.92 GERM CELL TUMOR
67 67 SAMIDAYAL 62 68344 ABD DISTENTION MNP-8 P6L3 3 3 52.6 473.4 MCA
68 68 CHINNAMMAL 24 73152 ABD PAIN IRREG P2L2 1 3 43.65 130.95 SCA
69 69 PAULTHAI 35 72967 ABD PAIN  RG P2L2/ST 1 1 8.35 8.35 SIMPLE SEROUS CYST
70 70 SELVI 40 70181 ABD PAIN RG P3L3/ST 1 1 16.86 16.86 SIMPLE SEROUS CYST
71 71 SUBBULAKSHMI 33 13076 ABD PAIN  IRRG P2L2/ST 1 1 71.48 71.48 SCA
72 72 SUMATHY 30 5764 ABD PAIN IRRG P2L2/ST 1 1 10.41 10.41  CORPUS LUTEAL CYST
73 73 THAVAMANI 47 4469 ABD PAIN  RG P5L2 1 3 20.74 62.22  SCA
74 74 MAHARASI 50 6400 ABD PAIN  MNP-2 P4L3/ST 3 1 24.65 73.95 SCA
75 75 KALYANI 45 7968 ABD PAIN RG P3L2/ST 1 1 19.82 19.82 SCA
76 76 PACKIYATHAI 35 6843 ABD PAIN IRRG P1L1 1 1 7.8 7.8 ENDOMETRIOTIC CYST
77 77 LAKSHMI 57 9339 ABD DISTENTION MNP-14 P6L4/ST 3 3 420.64 3785.76 SCC
78 78 PARVATHY 46 35132 ABD PAIN  RG P2L2 1 1 10.6 10.6 SIMPLE SEROUS CYST
79 79 MUTHAMMAL 38 36986 ABD PAIN IRRG P1L1 1 1 13.2 13.2 ENDOMETRIOTIC CYST
80 80 SARATHA 55 35822 ABD PAIN RG P1L2 1 1 11.53 11.53 DERMOID
81 81 SHANTHI 46 35549 ABD PAIN IRRG P2L2 1 3 44.82 134.46 SCA
82 82 LOGANAYAKI 51 21324 ABD.DISTENSION MNP-2 NP 3 3 498.4 4485.6 SCC
83 83 VALLI 41 36324 ABD PAIN RG NP 1 3 380.1 1140.3 SCC
84 84 CHANDRA 32 36424 ABD PAIN RG P1L0 1 1 55.39 55.39 SCA
85 85 MAHESHWARI 36 27364 ABD.DISTENSION RG P2L2/ST 1 3 12.48 37.44 SCA
86 86 ANJALI 45 26424 ABD.DISTENSION IRRG P3L3 1 3 14.6 43.8 MCA
87 87 MUTHUDEVI 31 21362 ABD.DISTENSION IRRG P2L2/ST 1 1 14.74 14.74 MCA
88 88 LAKSHMI 34 22632 ABD PAIN RG P2L2/ST 1 1 62.58 62.58 SCA
89 89 CHINNAPONNU 46 23134 ABD PAIN IRRG P2L2/ST 1 1 72.48 72.48 SCA
90 90 SUMATHY 30 34526 ABD PAIN RG P1L1 1 1 27.4 27.4 SCA
91 91 SUNDARI 46 23469 ABD PAIN RG P5L2 1 1 18.3 18.3 LUTEINISED THECOMA
92 92 KARPAGAVALLI 33 53024 ABD PAIN IRRG P2L2/ST 1 1 10 10 FOLLICULAR CYST
93 93 BACKIYALAKSHMI 56 19645 ABD.DISTENSION MNP-12 NP 3 1 10.5 31.5 SCC
94 94 SAVITHRI 34 3624 ABD PAIN RG P2L2/ST 1 1 72.8 72.8 SCA
95 95 VANITHA 40 67435 ABD PAIN RG P3L2 1 1 87.1 87.1 SCA
96 96 PARVATHY 55 10364 ABD PAIN, ABD.DISTENSION MNP-3 NP 3 3 12 108 MCC
97 97 PITCHAMMAL 50 10462 ABD PAIN IRRG P5L5/ST 1 1 75 75 SCA
98 98 RANI 32 14220 ABD PAIN RG P2L2/ST 1 1 8.3 8.3 SIMPLE SEROUS CYST
99 99 KALAIVANI 55 17321 ABD.DISTENSION MNP-6 P3L3 3 1 46.28 138.84 SCA
100 100 KUMARI 30 17643 ABD PAIN RG NP 1 1 9.4 9.4 DERMOID
